Provided by Tiger Trade Technology Pte. Ltd.

Amgen

430.34
-2.0850-0.48%
Volume:662.11K
Turnover:284.90M
Market Cap:231.73B
PE:26.73
High:431.85
Open:428.59
Low:426.00
Close:432.42
52wk High:447.03
52wk Low:269.77
Shares:538.48M
Float Shares:536.99M
Volume Ratio:0.42
T/O Rate:0.12%
Dividend:9.80
Dividend Rate:2.28%
EPS(TTM):16.10
EPS(LYR):14.23
ROE:91.47%
ROA:8.67%
PB:19.83
PE(LYR):30.24

Loading ...

Political and General News Events from August 24

Reuters
·
Aug 24

Daiichi Sankyo Names Ken Keller Chief Commercialization Officer, Effective April 2027

Reuters
·
Aug 24

Funds: What a Top Biotech Fund is Buying Now

Dow Jones
·
Aug 22

Amgen Advances Tarlatamab Shot vs. Infusion in Phase 3 Lung Cancer Study

TIPRANKS
·
Aug 22

Amgen is Maintained at Overweight by Piper Sandler

Dow Jones
·
Aug 21

Amgen price target raised to $457 from $427 at Piper Sandler

TIPRANKS
·
Aug 20

Sino Biopharmaceutical Stock Climbs 13% in Hong Kong, Outperforms Competitors

Dow Jones
·
Aug 20

U.S. Research Roundup-Amgen, Analog Devices, Moderna

Reuters
·
Aug 20

Amgen Inc Stock (AMGN) Moved Up by 3.19% on Aug 19: What Investors Need To Know

TradingKey
·
Aug 20

Why 2026 is Biotech's Comeback Year

Dow Jones
·
Aug 19

Movement Alert|Amgen Rises 3.05% in Regular Trading, Morgan Stanley and Mizuho Raise Target Prices Amid Biotech Sector Strength

Market Focus
·
Aug 19

Merck, Amgen Share Gains Contribute to Dow's 161-Point Climb

Dow Jones
·
Aug 19

Amgen is Maintained at Buy by Argus Research

Dow Jones
·
Aug 19

BetterLife Pharma Names Mahan Chehrenama Chief Medical Officer

Reuters
·
Aug 19

Amgen Inc : Argus Research Raises Target Price to $460

THOMSON REUTERS
·
Aug 19

Morgan Stanley Adjusts Price Target on Amgen to $362 From $351, Keeps Equalweight Rating

MT Newswires Live
·
Aug 19

What This Top Biotech Fund is Buying Now

Dow Jones
·
Aug 19

TScan Therapeutics Faces Loss of Key Amgen Partnership

TIPRANKS
·
Aug 19

TScan Therapeutics - Amgen to Terminate Research Collaboration and License Agreement with TScan Therapeutics - SEC Filing

THOMSON REUTERS
·
Aug 19

The Bull Case For Amgen (AMGN) Could Change Following Raised 2026 Earnings Guidance And Q2 Beat - Learn Why

Simply Wall St.
·
Aug 19